DelSiTech Announces Positive Topline Clinical Data From Phase 1 Trial With Its Sustained Release Eye Drop Platform
Turku, Finland – 29th June 2023: Drug delivery and development company DelSiTech today reported positive topline results from its Phase 1 clinical trial, evaluating the safety and tolerability of DST-2105, DelSiTech’s first of its kind, silica-based, long-acting demulcent eye drop product.
